US ovarian cancer mortality declined from 1999 to 2020, but significant disparities remain among older women, non-Hispanic White women, and those living in rural areas, as well as in the Northeastern ...

Katherine McDaniel, MD, a reproductive endocrinologist, discusses the key takeaways for oncologists treating patients of reproductive age.

The CARE Clinic at University of Colorado Hospital was developed to close treatment gaps caused by disparities in cancer care ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the growth stocks that could double by 2027. On July 14, CORT ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the 13 Best Low Risk High Growth Stocks to Buy. Analysts are ...

Corcept Therapeutics CORT announced that it has submitted a new drug application (NDA) to the FDA seeking approval for its ...

Detailed price information for Corcept Therapeutics (CORT-Q) from The Globe and Mail including charting and trades.

Corcept is developing relacorilant in ovarian cancer and a variety of other serious disorders, including endogenous hypercortisolism and prostate cancer. Relacorilant is proprietary to Corcept and is ...

DNA G-quadruplexes appear to substantially help ovarian cancer cells activate genes that counteract chemotherapy, effectively shielding the tumor from treatment.

Corcept Submits NDA For Relacorilant To Treat Platinum-Resistant Ovarian Cancer July 14, 2025 — 01:03 pm EDT Written by RTTNews.com for RTTNews -> ...

By Colin Kellaher Corcept Therapeutics has filed for U.S. Food and Drug Administration approval of its relacorilant drug candidate for the treatment of patients with platinum-resistant ovarian cancer.